Lyell Immunopharma says ronde-cel Phase 1/2 study in LBCL shows no grade 3+ CRS
PUBT · 06/12 16:45
Share
Listen to the news
- Lyell Immunopharma presented updated Phase 1/2 safety results for ronde-cel in relapsed or refractory large B-cell lymphoma at EHA 2026.
- Data showed a manageable safety profile with no severe cytokine release syndrome, supporting potential outpatient use.
- Separate translational findings, also presented at EHA, linked durable responses to the product’s manufacturing approach and dual CD19/CD20 targeting.
- The pivotal single-arm PiNACLE trial in third-line and later patients is set to deliver an updated dataset in 2H 2026.
- Lyell expects a pivotal readout in mid-2027, targeting a BLA submission in 2H 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606121245PRIMZONEFULLFEED9745993) on June 12, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved